Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants

Abstract Aim Atezolizumab and bevacizumab (Atezo/Bev) combination immunotherapy regimens and direct oral anticoagulants (DOACs) are both associated with bleeding. Therefore, combining Atezo/Bev regimens with DOACs may exacerbate the bleeding risk. This study investigated the feasibility of the Atezo...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Tasuku Nakabori, Kei Kunimasa, Masaki Kawabata, Sena Higashi, Kaori Mukai, Takahisa Kawamura, Takako Inoue, Motohiro Tamiya, Kazumi Nishino, Kazuyoshi Ohkawa
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Wiley 2024-06-01
Reeks:	Cancer Medicine
Onderwerpen:	atezolizumab and bevacizumab bleeding event combination immunotherapy direct oral anticoagulant hepatocellular carcinoma lung cancer
Online toegang:	https://doi.org/10.1002/cam4.7430
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!